Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of baricitinib in participants with primary biliary cholangitis who do not respond or cannot take UDCA has been terminated with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Primary Biliary Cholangitis | Phase 2 | Status: TERMINATED | Results posted: 2020-10-14